University of Manchester | GenomeWeb

University of Manchester

The circulating tumor cell-based classifier had an overall accuracy of 89 percent for small-cell lung cancer patients, the researchers reported.

The Stoller Biomarker Discovery Centre, funded by the UK's Medical Research Council, recently opened to develop mass spec-based research for varied diseases.

The company will use proceeds from the placement to conduct clinical trials on its Parsortix CTC system, which has been adopted by Cancer Research UK's Mancherster Institute.

Researchers at the annual meeting of the American Association for Cancer Research discussed their efforts to use genomics to protect patients from radiotherapy toxicity.

The funds will support the development of bioinformatics tools for use in clinical trials to provide more personalized healthcare for cancer patients

The partners received £30,000 (about $46,000) in funding from the BBSRC to support their metabolomics data-sharing and analyses activities.

The results provide early evidence for the ability of haplotypes in the HLA-DRB1 gene to predict outcome and drug response, which will have to be further replicated.

Cancer-ID is a newly created consortium tasked with validating blood-based biomarkers, such as CTC, cfDNA, and miRNA to bring liquid biopsies into the clinic.

NEW YORK (GenomeWeb) – The University of Manchester today said that it has been awarded £24 million ($38.5 million), including funding for omics-directed projects, from the UK government.

NEW YORK (GenomeWeb News) – A pair of genome sequencing studies published online yesterday in Nature Genetics is providing insights into the biology of parasitic whipworms, interactions with their hosts, and potential applications for treating inflammatory disease.

Pages

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.